Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Total Current Liabilities (2022 - 2026)

Sagimet Biosciences' Total Current Liabilities history spans 5 years, with the latest figure at $5.3 million for Q1 2026.

  • Quarterly Total Current Liabilities changed N/A to $5.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $5.3 million through Mar 2026, changed N/A year-over-year, with the annual reading at $5.1 million for FY2025, 14.53% up from the prior year.
  • Total Current Liabilities came in at $5.3 million for Q1 2026, up from $5.1 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $9.1 million in Q3 2025 to a low of $4.5 million in Q4 2024.
  • The 5-year median for Total Current Liabilities is $5.3 million (2023), against an average of $5.8 million.
  • Year-over-year, Total Current Liabilities decreased 21.22% in 2024 and then increased 14.53% in 2025.
  • Sagimet Biosciences' Total Current Liabilities stood at $5.3 million in 2022, then rose by 7.1% to $5.7 million in 2023, then fell by 21.22% to $4.5 million in 2024, then grew by 14.53% to $5.1 million in 2025, then rose by 3.84% to $5.3 million in 2026.
  • Per Business Quant, the three most recent readings for SGMT's Total Current Liabilities are $5.3 million (Q1 2026), $5.1 million (Q4 2025), and $9.1 million (Q3 2025).